Are Psychedelics as Effective as SSRIs for Depression?

In this Freethink interview, host Evan Baehr talks with Dr. Matthew Johnson, described as one of the most cited researchers in psychedelic therapy, about why he sees psychedelics as a fundamentally different approach to depression and addiction than standard antidepressants. The conversation covers the mental health crisis, how classic psychedelics work in the brain, and a field visit to a Mexican clinic treating opioid dependence with ibogaine. Johnson frames the therapy as demanding psychological work, not a quick fix, and is direct about real risks, including ibogaine's cardiac concerns.

A mental health crisis and the limits of SSRIs

Johnson points to a troubling data point: for the first time in recorded history, U.S. life expectancy has started decreasing, a trend he attributes largely to suicide and substance use. SSRIs, he says, are safer than 1950s antidepressants but not meaningfully more effective, and have hit a ceiling in how many people they help. He also notes a lower diagnostic threshold for depression today than in the 1960s, contributing to over-prescription. SSRIs were originally meant for short-term use, a window to make life changes before tapering off, but people often stay on them for years, and he says some evidence suggests the drugs numb a person rather than address the cause of their unhappiness.

What counts as a psychedelic

Johnson calls psychedelics "all arounders": magnifiers that can produce a blissful experience or a frightening one, rather than reliably up or down. He distinguishes the "classic psychedelics" (psilocybin, LSD, DMT as found in ayahuasca, and mescaline), acting on the serotonin 2A receptor, from MDMA (a different mechanism, releasing serotonin) and ketamine (acting on the glutamate system). Ibogaine and salvia divinorum round out the list.

Ibogaine and a clinic visit in Mexico

Ibogaine is best known, Johnson says, for its reported effect on opioid addiction: people describe it halting heroin cravings, and animal research shows it normalizes dopamine response patterns disrupted by addiction. He flags more caution here than with psilocybin or LSD, given ibogaine's cardiac risk.

The segment visits Beond, a Cancun clinic using ibogaine for opioid dependence and trauma. One guest describes a back injury, a prescribed oxycodone that became a years-long addiction, and a decade on Suboxone he could not taper off. Co-founder Talia Eisenberg says she started the clinic after an unsupervised ibogaine experience of her own ended her opiate cravings, prompting a model built on medical monitoring, preparation, and aftercare. Treatment runs roughly twelve hours under EKG monitoring; staff describe it as resetting the kappa-opioid receptor and serotonin activity, and upregulating a protein linked to a drive to change, a framing from the clinic rather than Johnson's research.

What may be happening in the brain

Johnson describes classic psychedelics as scrambling normal, localized communication between neighboring brain regions in favor of a surge of communication between regions that don't typically interact, comparing it to how the internet changed society's communication patterns. He ties this to how people often gain a more compassionate perspective on painful memories, since recall makes a memory malleable: a compelling new perspective formed in a session can become the memory that carries forward. He also cites neuroplasticity research in animals, framing therapy less as fixing the brain and more as clearing the way for its own healing tendency.

Which conditions show the most promise

Johnson names addiction and depression as the areas he is most excited about, seeing both as a person stuck in a rigid self-narrative that therapy can disrupt rather than only suppress. He cites his own pilot study using psilocybin for smoking cessation: against typical six-month quit rates of roughly 5 to 30 percent, his small open-label pilot reported 80 percent biologically confirmed abstinence at six months and 60 percent at two and a half years. Depression outcomes look similar, he says, with most participants no longer meeting criteria for depression. These figures come from small, early-stage research Johnson frames as promising, not conclusive.

Regulatory outlook and a common misconception

Johnson expects both MDMA and psilocybin to reach FDA-approved clinical use within a few years. MDMA for PTSD is furthest along, with two completed Phase III trials; psilocybin for depression and substance use disorders may follow, pending further trial data. He closes on the misconception he hears most: that psychedelic therapy is a "chemical crutch." He argues the opposite: people often describe sessions as the hardest thing they have done, and improvements seen months later reflect changes people made in their lives, not a lingering drug effect, since the substance clears the body within a day.

Johnson, on the difference from SSRIs: "They put life into your face... good psychedelic therapy tends to make you wanna take care of your stuff." More on preparation: set and setting and harm reduction.

Key takeaways

• ●Johnson ties decreasing U.S. life expectancy partly to suicide and substance use, and says SSRIs have plateaued in effectiveness despite decades of use.
• ●Classic psychedelics (psilocybin, LSD, DMT, mescaline) act on the serotonin 2A receptor; MDMA and ketamine work through different mechanisms.
• ●Ibogaine shows promise for opioid addiction by normalizing dopamine response, but carries cardiac risk and requires medical supervision.
• ●A featured Cancun clinic treats opioid dependence with ibogaine under a model of medical monitoring, preparation, and aftercare.
• ●Johnson's working theory: psychedelics scramble localized brain communication toward cross-region communication, which may underlie new perspectives on painful memories.
• ●His small pilot study found 80 percent smoking abstinence at six months, well above typical quit-rate ranges, though early-stage.
• ●He expects MDMA for PTSD and psilocybin for depression and substance use disorders to reach FDA approval within a few years, pending Phase III data.
• ●Johnson rejects the "chemical crutch" framing, describing the therapy as demanding work with lasting change in how people live.